Rollout of Closed-Loop Technology to Pregnant Women with Type 1 Diabetes : Healthcare Professionals' Views About Potential Challenges and Solutions
Aims: To explore healthcare professionals' views about the training and support needed to rollout closed-loop technology to pregnant women with type 1 diabetes. Methods: We interviewed (n = 19) healthcare professionals who supported pregnant women using CamAPS FX closed-loop during the Automated insulin Delivery Amongst Pregnant women with Type 1 diabetes (AiDAPT) trial. Data were analyzed descriptively. An online workshop involving (n = 15) trial team members was used to inform recommendations. Ethics approvals were obtained in conjunction with those for the wider trial. Results: Interviewees expressed enthusiasm for a national rollout of closed-loop, but anticipated various challenges, some specific to use during pregnancy. These included variations in insulin pump and continuous glucose monitoring expertise and difficulties embedding and retaining key skills, due to the relatively small numbers of pregnant women using closed-loop. Inexperienced staff also highlighted difficulties interpreting data downloads. To support rollout, interviewees recommended providing expert initial advice training, delivered by device manufacturers together with online training resources and specific checklists for different systems. They also highlighted a need for 24 h technical support, especially when supporting technology naive women after first transitioning onto closed-loop in early pregnancy. They further recommended providing case-based meetings and mentorship for inexperienced colleagues, including support interpreting data downloads. Interviewees were optimistic that if healthcare professionals received training and support, their long-term workloads could be reduced because closed-loop lessened women's need for glycemic management input, especially in later pregnancy. Conclusions: Interviewees identified challenges and opportunities to rolling-out closed-loop and provided practical suggestions to upskill inexperienced staff supporting pregnant women using closed-loop. A key priority will be to determine how best to develop mentorship services to support inexperienced staff delivering closed-loop. Clinical Trials Registration: NCT04938557.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Diabetes technology & therapeutics - 25(2023), 4 vom: 20. Apr., Seite 260-269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rankin, David [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.04.2023 Date Revised 06.04.2023 published: Print-Electronic ClinicalTrials.gov: NCT04938557 Citation Status MEDLINE |
|---|
| doi: |
10.1089/dia.2022.0479 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351733264 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351733264 | ||
| 003 | DE-627 | ||
| 005 | 20231226052107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/dia.2022.0479 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM351733264 | ||
| 035 | |a (NLM)36662589 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rankin, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rollout of Closed-Loop Technology to Pregnant Women with Type 1 Diabetes |b Healthcare Professionals' Views About Potential Challenges and Solutions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2023 | ||
| 500 | |a Date Revised 06.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04938557 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aims: To explore healthcare professionals' views about the training and support needed to rollout closed-loop technology to pregnant women with type 1 diabetes. Methods: We interviewed (n = 19) healthcare professionals who supported pregnant women using CamAPS FX closed-loop during the Automated insulin Delivery Amongst Pregnant women with Type 1 diabetes (AiDAPT) trial. Data were analyzed descriptively. An online workshop involving (n = 15) trial team members was used to inform recommendations. Ethics approvals were obtained in conjunction with those for the wider trial. Results: Interviewees expressed enthusiasm for a national rollout of closed-loop, but anticipated various challenges, some specific to use during pregnancy. These included variations in insulin pump and continuous glucose monitoring expertise and difficulties embedding and retaining key skills, due to the relatively small numbers of pregnant women using closed-loop. Inexperienced staff also highlighted difficulties interpreting data downloads. To support rollout, interviewees recommended providing expert initial advice training, delivered by device manufacturers together with online training resources and specific checklists for different systems. They also highlighted a need for 24 h technical support, especially when supporting technology naive women after first transitioning onto closed-loop in early pregnancy. They further recommended providing case-based meetings and mentorship for inexperienced colleagues, including support interpreting data downloads. Interviewees were optimistic that if healthcare professionals received training and support, their long-term workloads could be reduced because closed-loop lessened women's need for glycemic management input, especially in later pregnancy. Conclusions: Interviewees identified challenges and opportunities to rolling-out closed-loop and provided practical suggestions to upskill inexperienced staff supporting pregnant women using closed-loop. A key priority will be to determine how best to develop mentorship services to support inexperienced staff delivering closed-loop. Clinical Trials Registration: NCT04938557 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Closed-loop system | |
| 650 | 4 | |a Continuous glucose monitoring | |
| 650 | 4 | |a Healthcare professional | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Qualitative research | |
| 650 | 4 | |a Type 1 diabetes | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Hart, Ruth I |e verfasserin |4 aut | |
| 700 | 1 | |a Kimbell, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard-Kelly, Katharine |e verfasserin |4 aut | |
| 700 | 1 | |a Brackenridge, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Byrne, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Collett, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Dover, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a Hartnell, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Katharine F |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Tara T M |e verfasserin |4 aut | |
| 700 | 1 | |a Lindsay, Robert S |e verfasserin |4 aut | |
| 700 | 1 | |a McCance, David R |e verfasserin |4 aut | |
| 700 | 1 | |a McKelvey, Alastair |e verfasserin |4 aut | |
| 700 | 1 | |a Rayman, Gerry |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Rebecca M |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Eleanor M |e verfasserin |4 aut | |
| 700 | 1 | |a White, Sara L |e verfasserin |4 aut | |
| 700 | 1 | |a Hovorka, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Helen R |e verfasserin |4 aut | |
| 700 | 1 | |a Lawton, Julia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes technology & therapeutics |d 1999 |g 25(2023), 4 vom: 20. Apr., Seite 260-269 |w (DE-627)NLM113690495 |x 1557-8593 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:4 |g day:20 |g month:04 |g pages:260-269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/dia.2022.0479 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 4 |b 20 |c 04 |h 260-269 | ||